NHS England strikes deal to make innovative multiple sclerosis drug available

Patients with multiple sclerosis (MS) will have routine access to a drug that can slow disability under a deal struck between NHS England and the manufacturer Roche, paving the way for its approval by NICE. Ocrelizumab (also known as Ocrevus) is the first treatment that can modify or change the course of the disease to be available for patients who have primary progressive multiple sclerosis, where symptoms steadily increase over a period of months or years without periods of remission. Clinical trial results show that ocrelizumab can slow the worsening of disability in people with the condition, helping patients stay